SAN DIEGO & SINGAPORE–(BUSINESS WIRE)–ImmunoScape, a biotechnology company focused on next-generation T Cell receptor (TCR)-based immunotherapies, today announced that three abstracts have been accepted for poster presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting taking place April 5-10, 2024 in San Diego, California.
Presentation details are as follows:
Title: Discovery and development of T cell receptors targeting MAGE family antigens for adoptive T cell therapy against solid tumorsÂ
Presenter: Juliana Velez Lujan, Ph.D., ImmunoScape, Senior ScientistÂ
Session Title: Adoptive Cell Therapies 1: Tumor Antigen-Specific T-cells and TCR-TÂ
Date & Time: Sunday, April 7, 2024, 1:30 p.m. – 5:00 p.m. PTÂ
Location: Poster Section 1Â
Poster Number: 13
Title: Deep Immunomics pipeline for discovery and validation of novel cancer-specific T cell receptorsÂ
Presenter: Hannah Fields, ImmunoScape, ScientistÂ
Session Title: Adoptive Cell Therapies 1: Tumor Antigen Specific T-cells and TCR-TÂ
Date & Time: Sunday, April 7, 2024, 1:30 p.m. – 5:00 p.m. PTÂ
Location: Poster Section 1Â
Poster Number: 8
Title: A validated bioinformatics tool-set for predicting TCR specificityÂ
Presenter: Andreas Wilm, ImmunoScape, Director of Computational BiologyÂ
Session Title: Database Resources, Statistical Methods, and Other ToolsÂ
Date & Time: Monday, April 8, 2024, 1:30 p.m. – 5:00 p.m. PTÂ
Location: Poster Section 36Â
Poster Number: 19
Full abstracts will be available on the AACR Online Program Planner. Following the conference, the posters will be made available under the “Publications†page on ImmunoScape’s website.
About ImmunoScape
ImmunoScape is a biotechnology company focused on the discovery and development of next-generation TCR cell therapies in the field of oncology. The company’s proprietary Deep Immunomics technology and machine learning platforms enable highly sensitive, large-scale mining and immune profiling of T cells in cancer patient samples to identify novel, therapeutically relevant TCRs across multiple types of solid tumors. ImmunoScape has multiple discovery programs ongoing and will be progressing towards IND-enabling studies and entry into the clinic. For more information, please visit https://immunoscape.com/.
Contacts
Media
Kalyn Schieffer for ImmunoScape
[email protected]
